Compare SPDR Gold Trust (GLD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Sana Biotechnology Inc — how do they compare? SPDR Gold Trust trades at $384.58 (market cap $139.66B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: SPDR Gold Trust is far larger — about 166.9× Sana Biotechnology Inc's market cap, and SPDR Gold Trust is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Sana Biotechnology Inc for 23 Days on average.
| GLD | SANA | |
|---|---|---|
Market Cap | $139.66B | $836.71M |
Volume | 9,544,773 | 4,507,444 |
52-Week High | $495.90 | $5.92 |
52-Week Low | $362.32 | $2.68 |
Typical Hold Time | 74 Days | 23 Days |
Sector | — | Health |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD trades at $378.67, up 0.74% with bearish technical signals dominating as 17 indicators signal sell versus 2 buy signals. The stock faces resistance at $380-$384 while finding support at $377-$373. Recent news highlights pressure from rising Treasury yields and dollar strength overwhelming safe-haven demand, with gold failing to sustain gains despite weak employment data.
The outlook remains cautious with technical indicators signaling bearish momentum and fundamental data unavailable. Key risks include persistent rate hike expectations and dollar strength, though some analysts see tactical buying opportunities. Investors should monitor Fed policy decisions and inflation trends for directional catalysts.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
